Bifogade filer
Strong CERAMENT® Results Presented at EBJIS
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
BONESUPPORT™, a leading company in orthobiology for the treatment of bone injuries, announced that strong study results were presented at the European Bone and Joint Infection Society (EBJIS) meeting, September 11–13, 2025. The study which was conducted in South Africa, demonstrates that CERAMENT® G and CERAMENT® V can deliver the same excellent outcomes for trauma patients with infection in a developing market as previously shown in studies from, among others, the Oxford Bone Infection Unit, UK.
The study included 103 patients with post-traumatic infection (80% with open fractures and 20% with closed fractures) or chronic bone infection, treated with CERAMENT G or CERAMENT V in a one-stage procedure. At follow-up after 11 months, treatment success, defined as complete regression of infection without recurrence, as observed in 96.1% of patients. No patients required amputation. The results confirm that CERAMENT is both effective and safe, even in resource-limited settings.
The study is particularly significant as it focuses on trauma patients who developed infections, a clinically complex and resource-demanding patient group. Achieving these results in a developing market shows that CERAMENT is not dependent on advanced infrastructure but can be used broadly and effectively. A previous study from the Oxford Bone Infection Unit demonstrated 94% infection-free outcomes after six years (96% after one year), results which are now confirmed in a new context.
“The study shows that CERAMENT works even in countries with limited resources. Its simplicity, versatility, and clinical effectiveness give us great confidence in its global potential,” said Torbjörn Sköld, CEO of BONESUPPORT.